comparemela.com

Latest Breaking News On - Renal dysfunction - Page 4 : comparemela.com

Cureus | Outcomes With Left Ventricular Assist Device in End-Stage Renal Disease: A Systematic Review

Renal dysfunction is a common comorbidity in patients with advanced heart failure who may benefit from mechanical circulatory support (MCS). Unfortunately, renal function may result after left ventricular assist device (LVAD) implantation. The purpose of this study is to examine the outcomes of advanced heart failure patients with end-stage renal disease (ESRD) requiring mechanical circulatory support as a bridge to transplant (BTT) or destination therapy (DT). We searched Medline, Embase, and Cochrane in September 2021. The following keywords were used: left ventricular assist device or LVAD and end-stage renal disease or ESRD. Our study included case reports, case series, descriptive studies, and randomized control trials. Review articles, guidelines, systematic reviews, and meta-analyses were excluded. We also excluded pediatric cases. We identified 278 articles; 92 were duplicated, 186 articles entered the screening phase, and 133 articles were excluded by title and abstract. After

Sasural Simar Ka Actor Ashiesh Roy Hospitalised Due To Renal Dysfunction

Bristol Myers Squibb Receives European Commission Approval for Opdivo + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma

Approval is based on positive results from the Phase 3 CheckMate -649 trial Opdivo plus chemotherapy is the first treatment regimen to demonstrate superior overall survival and progression-free survival compared to chemotherapy alone in this patient population Bristol Myers Squibb Receives European Commission Approval for Opdivo  + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, .

U S Food and Drug Administration Accepts Bristol Myers Squibb s Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

U S Food and Drug Administration Accepts Bristol Myers Squibb s Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.